BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf 2015;6:189-95. [PMID: 26478806 DOI: 10.1177/2042098615595359] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Pagel JF, Pandi-perumal SR, Monti JM. Treating insomnia with medications. Sleep Science Practice 2018;2. [DOI: 10.1186/s41606-018-0025-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
2 Blais A, Drouin G, Chaumontet C, Voisin T, Couvelard A, Even PC, Couvineau A. Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS One 2017;12:e0169908. [PMID: 28085909 DOI: 10.1371/journal.pone.0169908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
3 Okino K, Yamada H, Tomioka H, Nozaki S, Iwanami A, Inamoto A. Use of Suvorexant and Antipsychotics in the Treatment of Delirium After Infectious Diseases: A Retrospective Study. J Clin Psychopharmacol 2021;41:589-93. [PMID: 34411006 DOI: 10.1097/JCP.0000000000001450] [Reference Citation Analysis]
4 Patel D, Steinberg J, Patel P. Insomnia in the Elderly: A Review. J Clin Sleep Med 2018;14:1017-24. [PMID: 29852897 DOI: 10.5664/jcsm.7172] [Cited by in Crossref: 94] [Cited by in F6Publishing: 77] [Article Influence: 23.5] [Reference Citation Analysis]
5 Elam HB, Perez SM, Donegan JJ, Lodge DJ. Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Transl Psychiatry 2021;11:114. [PMID: 33558469 DOI: 10.1038/s41398-021-01235-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Mehr JB, Mitchison D, Bowrey HE, James MH. Sleep dysregulation in binge eating disorder and "food addiction": the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 2021. [PMID: 34145404 DOI: 10.1038/s41386-021-01052-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
8 Perez SM, Lodge DJ. Orexin Modulation of VTA Dopamine Neuron Activity: Relevance to Schizophrenia. Int J Neuropsychopharmacol 2021;24:344-53. [PMID: 33587746 DOI: 10.1093/ijnp/pyaa080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Black J, Pillar G, Hedner J, Polo O, Berkani O, Mangialaio S, Hmissi A, Zammit G, Hajak G. Efficacy and safety of almorexant in adult chronic insomnia: a randomized placebo-controlled trial with an active reference. Sleep Med 2017;36:86-94. [PMID: 28735928 DOI: 10.1016/j.sleep.2017.05.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
10 Inoue Y, Watanabe T, Takashima S, Takase T, Ishikawa K, Kubota N, Yardley J, Moline M. Efficacy and safety of lemborexant in adults with insomnia: comparing Japanese and non-Japanese subgroups from the global, phase 3, randomized, double-blind, placebo-controlled SUNRISE 2 study. J Clin Sleep Med 2021;17:1067-74. [PMID: 33576735 DOI: 10.5664/jcsm.9148] [Reference Citation Analysis]
11 Kuriyama A, Tabata H. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis. Sleep Med Rev 2017;35:1-7. [PMID: 28365447 DOI: 10.1016/j.smrv.2016.09.004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
12 Matsumura T, Terada J, Yoshimura C, Koshikawa K, Kinoshita T, Yahaba M, Nagashima K, Sakao S, Tatsumi K. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience. Drug Des Devel Ther 2019;13:809-16. [PMID: 30880914 DOI: 10.2147/DDDT.S197237] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
13 Suzuki K, Miyamoto M, Hirata K. Sleep disorders in the elderly: Diagnosis and management. J Gen Fam Med 2017;18:61-71. [PMID: 29263993 DOI: 10.1002/jgf2.27] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
14 Skillman B, Kerrigan S. CYP450-Mediated metabolism of suvorexant and investigation of metabolites in forensic case specimens. Forensic Sci Int 2020;312:110307. [PMID: 32473525 DOI: 10.1016/j.forsciint.2020.110307] [Reference Citation Analysis]
15 Choi Y, Raymer BK. Sleep modulating agents. Bioorg Med Chem Lett 2019;29:2025-33. [PMID: 31307886 DOI: 10.1016/j.bmcl.2019.06.043] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Izuhara M, Kawano K, Otsuki K, Hashioka S, Inagaki M. Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients. Sleep Med 2021;80:100-4. [PMID: 33588260 DOI: 10.1016/j.sleep.2021.01.030] [Reference Citation Analysis]
17 Nevárez N, de Lecea L. Hypocretin and the Regulation of Sleep-Wake Transitions. Handbook of Sleep Research. Elsevier; 2019. pp. 89-99. [DOI: 10.1016/b978-0-12-813743-7.00006-2] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Ohsako N, Hashimoto T, Shiko Y, Kawasaki Y, Nakagawa M, Okuma T, Kurata T, Suzuki H, Ishige M, Kikuchi S. Pharmacotherapy for elderly patients with delirium in a general ward setting: a retrospective study. Asian Journal of Psychiatry 2022. [DOI: 10.1016/j.ajp.2022.103024] [Reference Citation Analysis]
19 Gamble MC, Katsuki F, McCoy JG, Strecker RE, McKenna JT. The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience 2021;463:30-44. [PMID: 33737028 DOI: 10.1016/j.neuroscience.2021.03.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Madari S, Golebiowski R, Mansukhani MP, Kolla BP. Pharmacological Management of Insomnia. Neurotherapeutics 2021;18:44-52. [PMID: 33527255 DOI: 10.1007/s13311-021-01010-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Herring WJ, Roth T, Krystal AD, Michelson D. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. J Sleep Res 2018;28. [DOI: 10.1111/jsr.12782] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mezeiova E, Janockova J, Konecny J, Kobrlova T, Benkova M, Dolezal R, Prchal L, Karasova-Zdarova J, Soukup O, Korabecny J. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorg Chem 2020;103:104179. [PMID: 32891860 DOI: 10.1016/j.bioorg.2020.104179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Jee HJ, Shin W, Jung HJ, Kim B, Lee BK, Jung YS. Impact of Sleep Disorder as a Risk Factor for Dementia in Men and Women. Biomol Ther (Seoul) 2020;28:58-73. [PMID: 31838834 DOI: 10.4062/biomolther.2019.192] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
24 Petrous J, Furmaga K. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts. BMJ Case Rep 2017;2017:bcr-2017-222037. [PMID: 29066641 DOI: 10.1136/bcr-2017-222037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Rajana N, Devi DR, Kumar Reddy DN, Babu JM, Basavaiah K, Balakumaran K. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC. J Chromatogr Sci 2020;58:433-44. [PMID: 32134104 DOI: 10.1093/chromsci/bmaa003] [Reference Citation Analysis]
26 Li SB, Nevárez N, Giardino WJ, de Lecea L. Optical probing of orexin/hypocretin receptor antagonists. Sleep 2018;41. [PMID: 30060151 DOI: 10.1093/sleep/zsy141] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
27 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
28 Brooks S, Jacobs GE, de Boer P, Kent JM, Van Nueten L, van Amerongen G, Zuiker R, Kezic I, Luthringer R, van der Ark P, van Gerven JM, Drevets W. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. J Psychopharmacol 2019;33:202-9. [DOI: 10.1177/0269881118822258] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
29 Azuma K, Takaesu Y, Soeda H, Iguchi A, Uchida K, Ohta S, Mishima S, Inoue T, Inoue Y, Oda J. Ability of suvorexant to prevent delirium in patients in the intensive care unit: a randomized controlled trial. Acute Med Surg 2018;5:362-8. [PMID: 30338083 DOI: 10.1002/ams2.368] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kaushik MK, Aritake K, Cherasse Y, Imanishi A, Kanbayashi T, Urade Y, Yanagisawa M. Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 2021:zsab043. [PMID: 33609365 DOI: 10.1093/sleep/zsab043] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]